Overview
Dassault Systèmes shares rose about 2% on Thursday after the French software maker posted second‑quarter results that beat consensus estimates and announced a strategic acquisition of life‑sciences software firm ArisGlobal valued at up to $2 billion.
Financial Performance
The company reported total IFRS revenue of €1.56 billion for Q2, a 2% increase on a reported basis and a 4.1% rise in constant‑currency terms, placing the result roughly one percentage point above Morgan Stanley and consensus forecasts and near the top of its own 2‑5% guidance range. Adjusted earnings per share were €0.31, surpassing the broker’s estimate by 4%. Non‑IFRS operating margin expanded to 30% from 29.3% a year earlier, beating Morgan Stanley’s forecast by 2 percentage points. Free cash flow amounted to €214 million, covering 46% of adjusted EBIT, short of the 63% coverage expected by analysts.
Segment Highlights
Industrial Innovation software revenue grew 5%, while Mainstream Innovation posted an 8% increase. Life sciences software declined 4% to €252.2 million, with the flagship MEDIDATA product down 3%, reflecting a three‑year growth challenge noted by Morgan Stanley. Regional performance showed Americas revenue up 5%, Europe flat due to auto‑sector weakness, and Asia up 8% despite a decline in China.
Acquisition Details
Dassault announced the same‑day acquisition of ArisGlobal, a safety and regulatory intelligence firm, structured as $1.8 billion payable upfront plus up to $200 million contingent on AI‑related revenue milestones. CEO Pascal Daloz said the deal will create “the industry’s first AI platform that unifies real‑world evidence with virtual evidence.” ArisGlobal is projected to generate $175 million in revenue for 2026, implying a valuation of 10.3× revenue on the upfront payment and 11.4× when including the earn‑out. Management expects the transaction to be accretive to both revenue and EPS in the first year, with closing targeted for the second half of 2026 pending regulatory approval.
Guidance and Outlook
Dassault reaffirmed its full‑year guidance of 3‑5% constant‑currency revenue growth, an adjusted EBIT margin of 32.2‑32.6%, and adjusted EPS growth of 3‑6%. Third‑quarter revenue is projected between €1.497 billion and €1.537 billion. The annual run‑rate rose 6% to €4.44 billion, and first‑half operating cash flow increased 11% to €1.24 billion.
Analyst Commentary
Morgan Stanley maintains an “equal‑weight” rating with a target price of €21.75, describing the quarter as “in‑line to slightly better than feared” and noting that the growth pace should allow a relatively smooth path to full‑year guidance. The firm highlighted the life‑sciences segment’s ongoing challenges and flagged the acquisition’s valuation multiples as a potential concern for some investors. AlphaSignals rated the impact of the results on its thesis as unchanged, with the consensus beat providing modest upside.